BR112018016310A2 - métodos para uso de agonistas de fxr - Google Patents
métodos para uso de agonistas de fxrInfo
- Publication number
- BR112018016310A2 BR112018016310A2 BR112018016310-4A BR112018016310A BR112018016310A2 BR 112018016310 A2 BR112018016310 A2 BR 112018016310A2 BR 112018016310 A BR112018016310 A BR 112018016310A BR 112018016310 A2 BR112018016310 A2 BR 112018016310A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- fxr agonists
- fxr
- agonists
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente invenção provê métodos para modulação de atividade de receptores farnesoide x (fxr) usando específicos agonistas de fxr, em particular para tratamento ou prevenção de doenças do fígado.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298121P | 2016-02-22 | 2016-02-22 | |
| US62/298,121 | 2016-02-22 | ||
| US201662420661P | 2016-12-12 | 2016-12-12 | |
| US62/420,661 | 2016-12-12 | ||
| PCT/IB2017/050963 WO2017145041A1 (en) | 2016-02-22 | 2017-02-20 | Methods for using fxr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018016310A2 true BR112018016310A2 (pt) | 2018-12-26 |
Family
ID=58231666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018016310-4A BR112018016310A2 (pt) | 2016-02-22 | 2017-02-20 | métodos para uso de agonistas de fxr |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11344540B2 (pt) |
| EP (2) | EP3419625B1 (pt) |
| JP (1) | JP6986022B2 (pt) |
| KR (1) | KR20180115270A (pt) |
| CN (2) | CN108697702A (pt) |
| AU (1) | AU2017223155B2 (pt) |
| BR (1) | BR112018016310A2 (pt) |
| CA (1) | CA3013186A1 (pt) |
| CL (1) | CL2018002359A1 (pt) |
| CY (1) | CY1124300T1 (pt) |
| DK (1) | DK3419625T3 (pt) |
| ES (1) | ES2878575T3 (pt) |
| HK (1) | HK1257647A1 (pt) |
| HR (1) | HRP20211032T1 (pt) |
| HU (1) | HUE054819T2 (pt) |
| IL (1) | IL260784B (pt) |
| LT (1) | LT3419625T (pt) |
| MX (1) | MX2018010100A (pt) |
| PH (1) | PH12018501656A1 (pt) |
| PL (1) | PL3419625T3 (pt) |
| PT (1) | PT3419625T (pt) |
| RU (1) | RU2743075C2 (pt) |
| SI (1) | SI3419625T1 (pt) |
| TW (1) | TWI735546B (pt) |
| WO (1) | WO2017145041A1 (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3277286T3 (da) | 2015-03-31 | 2021-07-05 | Enanta Pharm Inc | Galdesydererivater som fxr/tgr5-agonister og anvendelsesmetoder deraf |
| PT3419624T (pt) | 2016-02-22 | 2021-04-07 | Novartis Ag | Métodos para utilizar agonistas de fxr |
| US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
| GB201616670D0 (en) * | 2016-09-30 | 2016-11-16 | Innospec Ltd | Methods, compositions and uses relating thereto |
| WO2018067704A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| AR114930A1 (es) | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
| WO2019089670A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| WO2019089664A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid x receptor modulators |
| PE20201170A1 (es) | 2017-11-01 | 2020-10-28 | Bristol Myers Squibb Co | Compuestos biciclicos en puente como moduladores del receptor farnesoide x |
| AU2018357878A1 (en) | 2017-11-01 | 2020-06-18 | Bristol-Myers Squibb Company | Spirocyclic compounds as farnesoid X receptor modulators |
| KR20200083529A (ko) | 2017-11-01 | 2020-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물 |
| TW201936189A (zh) * | 2017-11-30 | 2019-09-16 | 瑞士商諾華公司 | 用於使用fxr激動劑之方法 |
| WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US20220227804A1 (en) * | 2019-05-29 | 2022-07-21 | Qing Bile Therapeutics Inc. | Combination of a polyhydroxylated bile acid and a farnesoid x receptor agonist |
| KR20220035365A (ko) | 2019-07-18 | 2022-03-22 | 엔요 파마 | 인터페론의 부작용을 감소시키는 방법 |
| WO2021044351A1 (en) * | 2019-09-06 | 2021-03-11 | Novartis Ag | Methods of treating liver disease using lta4h inhibitors |
| WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Ｅｎｙｏ製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| TR201807321T4 (tr) | 2013-11-05 | 2018-06-21 | Novartis Ag | Farnesoid x reseptörlerinin modüle edilmesi için bileşimler ve yöntemler. |
| JP6431083B2 (ja) | 2014-02-20 | 2018-11-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｆｇｆ−１８化合物の投与計画 |
| AU2017223148B2 (en) * | 2016-02-22 | 2019-07-18 | Novartis Ag | Methods for using FXR agonists |
| PT3419624T (pt) | 2016-02-22 | 2021-04-07 | Novartis Ag | Métodos para utilizar agonistas de fxr |
-
2017
- 2017-02-20 ES ES17709189T patent/ES2878575T3/es active Active
- 2017-02-20 HU HUE17709189A patent/HUE054819T2/hu unknown
- 2017-02-20 BR BR112018016310-4A patent/BR112018016310A2/pt not_active Application Discontinuation
- 2017-02-20 KR KR1020187023682A patent/KR20180115270A/ko unknown
- 2017-02-20 CN CN201780010381.3A patent/CN108697702A/zh active Pending
- 2017-02-20 EP EP17709189.9A patent/EP3419625B1/en active Active
- 2017-02-20 PT PT177091899T patent/PT3419625T/pt unknown
- 2017-02-20 DK DK17709189.9T patent/DK3419625T3/da active
- 2017-02-20 CN CN202111030869.7A patent/CN113679718A/zh active Pending
- 2017-02-20 WO PCT/IB2017/050963 patent/WO2017145041A1/en active Application Filing
- 2017-02-20 EP EP21152135.6A patent/EP3848031A1/en not_active Withdrawn
- 2017-02-20 PL PL17709189T patent/PL3419625T3/pl unknown
- 2017-02-20 LT LTEP17709189.9T patent/LT3419625T/lt unknown
- 2017-02-20 AU AU2017223155A patent/AU2017223155B2/en not_active Ceased
- 2017-02-20 JP JP2018544236A patent/JP6986022B2/ja active Active
- 2017-02-20 CA CA3013186A patent/CA3013186A1/en active Pending
- 2017-02-20 RU RU2018133298A patent/RU2743075C2/ru active
- 2017-02-20 MX MX2018010100A patent/MX2018010100A/es unknown
- 2017-02-20 US US16/078,409 patent/US11344540B2/en active Active
- 2017-02-20 SI SI201730836T patent/SI3419625T1/sl unknown
- 2017-02-22 TW TW106105850A patent/TWI735546B/zh not_active IP Right Cessation
-
2018
- 2018-07-25 IL IL260784A patent/IL260784B/en unknown
- 2018-08-03 PH PH12018501656A patent/PH12018501656A1/en unknown
- 2018-08-17 CL CL2018002359A patent/CL2018002359A1/es unknown
-
2019
- 2019-01-02 HK HK19100005.2A patent/HK1257647A1/zh unknown
-
2021
- 2021-06-29 HR HRP20211032TT patent/HRP20211032T1/hr unknown
- 2021-07-05 CY CY20211100600T patent/CY1124300T1/el unknown
-
2022
- 2022-04-26 US US17/660,673 patent/US20220313677A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018016310A2 (pt) | métodos para uso de agonistas de fxr | |
| CY1122653T1 (el) | Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων | |
| BR112015032718A2 (pt) | composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos | |
| BR112019012342A2 (pt) | anticorpos il-11 | |
| CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| MX2023008759A (es) | Emulsion de rejuvenecimiento de asfalto biobasado. | |
| BR112016013963A2 (pt) | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 | |
| BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
| BR112017004141B8 (pt) | Agente de imagemamento e seu uso | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| CL2016002667A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
| CY1123007T1 (el) | Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2b | |
| CR20160362A (es) | Anticuerpos anti-jagged1 y metodos de uso | |
| BR112015022604A2 (pt) | usos de um modulador de modificador de cromatina e um antagonista de egfr | |
| ES1220316Y (es) | Dispositivo de agarre, sistema y herramientas para la fijacion de placas de barandillas. | |
| BR112019018124A2 (pt) | composições e métodos para imunooncologia | |
| BR112018000187A2 (pt) | composto, composição, método, e, uso de um composto ou composição | |
| BR112017002662A2 (pt) | processo para preparar furfural e/ou derivados de furfural. | |
| BR112017006515A8 (pt) | moléculas biespecíficas, composições, método para tratar ou prevenir infecção por hiv-1 em um indivíduo com essa necessidade, e vetor | |
| ES2725300B4 (es) | Maquina y procedimiento para posicionar objetos. | |
| BR112018008757A2 (pt) | suspensor de liner | |
| BR112017004136A2 (pt) | sondas para imageamento de proteína de huntingtina | |
| BR112018075135A2 (pt) | combinações farmacêuticas para tratar câncer | |
| BR112018073871A2 (pt) | dispensador, e, método. | |
| BR112018008375A2 (pt) | novos anti estrogênios heterocíclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |